Research publications

Alfred Health research outcomes are published in a wide range of peer reviewed journals. 

Search or browse research publications by year, research area, publication type or keyword.

Clear filter
Publication Details
Phase 3 trial of concizumab in hemophilia with inhibitors

Matsushita T, Shapiro A, Abraham A, Angchaisuksiri P, Castaman G, Cepo K, d'Oiron R, Frei-Jones M, Goh AS, Haaning J, Hald Jacobsen S, Mahlangu J, Mathias M, Nogami K, Skovgaard Rasmussen J, Stasyshyn O, Tran H, Vilchevska K, Villarreal Martinez L, Windyga J, You CW, Zozulya N, Zulfikar B, Jiménez-Yuste V; explorer7 Investigators.

(2023), New England journal of medicine, 389(9), 783-794

DOI: 10.1056/NEJMoa2216455

The prognostic impact of t(11;14) in multiple myeloma: A real-world analysis from the Australian Lymphoma Leukaemia Group (ALLG) and the Australian Myeloma and Related Diseases Registry (MRDR)

Lim, K. J., Wellard, C., Talaulikar, D., Tan, J. L., Loh, J., Puvanakumar, P., Kuzich, J. A., Ho, M., Murphy, M., Zeglinas, N., Low, M. S., Routledge, D., Lim, A. B., Gibbs, S. D., Quach, H., Morgan, S., Moore, E., & Ninkovic, S

(2023), EJHaem, 4(3), 639-46

DOI: 10.1002/jha2.742

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study

Gerds AT, Verstovsek S, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M, Fox ML, McLornan D, Perkins A, Yoon SS, Gupta V, Kiladjian JJ, Granacher N, Lee SE, Ocroteala L, Passamonti F, Harrison CN, Oh S, Klencke BJ, Yu J, Donahue R, Kawashima J, Mesa R

(2023), Lancet Haematology, 10(9), e735-e746

DOI: 10.1016/S2352-3026(23)00174-6

Haemophilia joint score (HJHS) usage, patterns and outcome data in patients with haemophilia A and haemophilia B in Australia: a descriptive study using the Australian Bleeding Disorders Registry (ABDR)

George C, Parikh S, Carter T, Morris A, Cramey C, Mcelroy K, Tran H

(2023), Haemophilia, 29(4), 1135-1141

DOI: 10.1111/hae.14812

Evaluation of treatment and outcome for patients with haemophilia A and haemophilia B on extended half-life (EHL) factor products: A 12-month data analysis

George C, Parikh S, Carter T, Mccosker J, Carlino S, Tran H

(2023), Haemophilia, 29(5), 1283-1290

DOI: 10.1111/hae.14842

TP53 status and impact on AML prognosis within the ELN 2022 risk classification

Fleming S, Tsai XC, Morris R, Hou HA, Wei AH

(2023), Blood, 142(23), 2029-2033

DOI: 10.1182/blood.2023020855

Adherence and persistence to direct factor Xa inhibitors in the community following newly diagnosed venous thromboembolism: a retrospective pharmacy-linkage study

Dix C, Bortz H, da Gama M, Treloar M, Reynolds M, Ramanan R, Day T, Tran H

(2023), International journal of pharmacy practice, 31(5), 528-533

DOI: 10.1093/ijpp/riad053

Normalisation of haemoglobin and control of breakthrough haemolysis with increased frequency pegcetacoplan dosing in treated paroxysmal nocturnal haemoglobinuria

Davis, A. K., Bingham, N., & Szer, J

(2023), EJHaem, 4(3), 710-713

DOI: 10.1002/jha2.714

Immune thrombocytopenia and COVID-19 vaccination: outcomes and comparisons to prepandemic patients

Choi PY, Hsu D, Tran HA, Tan CW, Enjeti A, Chen VMY, Merriman E, Yong ASM, Simpson J, Gardiner E, Cherbuin N, Curnow J, Pepperell D, Bird R.

(2023), Research and practice in thrombosis and haemostasis, 7(1), 100009

DOI: 10.1016/j.rpth.2022.100009

A Novel RUNX1 Genetic Variant Identified in a Young Male with Severe Osteoporosis

Block TJ, Shore-Lorenti C, Zebaze R, Kerr PG, Kalff A, Perkins AC, Ebeling PR, Milat F

(2023), JBMR Plus, 7(9), e10791

DOI: 10.1002/jbm4.10791

Direct oral anticoagulants or vitamin K antagonists in emergencies: comparison of management in an observational study

Baker RI, Gilmore G, Chen V, Young L, Merriman E, Curnow J, Joseph J, Tiao JY, Chih J, McRae S, Harper P, Tan CW, Brighton T, Royle G, Hugman A, Hankey GJ, Crowther H, Boey J, Gallus A, Campbell P, Tran H; Thrombosis and Haemostasis Society of Australia and New Zealand Anticoagulation Reversal and Events Study Collaborative

(2023), Research and practice in thrombosis and haemostasis, 7(5), 100196

DOI: 10.1016/j.rpth.2023.100196

Genomic dissection of endemic carbapenem resistance reveals metallo-beta-lactamase dissemination through clonal, plasmid and integron transfer

Macesic N, Hawkey J, Vezina B, Wisniewski JA, Cottingham H, Blakeway LV, Harshegyi T, Pragastis K, Badoordeen GZ, Dennison A, Spelman DW, Jenney AWJ, Peleg AY

(2023), Nature communications, 14(1), 4764

DOI: 10.1038/s41467-023-39915-2

Antimicrobial susceptibility of bacterial isolates from clinical specimens in four Pacific Island countries, 2017-2021

Loftus MJ, Everts RJ, Cheng AC, Eti P, Fakasiieiki T, Isaia L, Isopo E, Jenney AWJ, Lameko V, Leaupepe H, Leavai F, Lee SJ, Moungaevalu M, Stewardson AJ, Tekoaua R, Tou D, Wuatai G, Peleg AY

(2023), LANCET REGIONAL HEALTH-WESTERN PACIFIC, 32, 100677

DOI: 10.1016/j.lanwpc.2022.100677

Antimicrobial susceptibility of ceftolozane-tazobactam against multidrug-resistant Pseudomonas aeruginosa isolates from Melbourne, Australia

Kostoulias, Polyxeni; Chang, Christina Catherine; Wisniewski, Jessica Ann; Abbott, Iain Joseph; Zisis, Helen; Dennison, Amanda M.; Spelman, Denis William; Peleg, Anton Yariv

(2023), Pathology, 55(5), 663-668

DOI: 10.1016/j.pathol.2023.03.009

Anti-factor-Xa and activated partial thromboplastin time concordance and outcomes in adults undergoing extracorporeal membrane oxygenation: a secondary analysis of the pilot low-dose heparin in critically ill patients undergoing extracorporeal membrane oxygenation randomized trial

Aubron C, Chapalain X, Bailey M, Board J, Buhr H, Cartwright B, Dennis M, Hodgson C, Forrest P, McIlroy D, Murphy D, Murray L, Pellegrino V, Pilcher D, Sheldrake J, Tran H, Vallance S, Cooper DJ, McQuilten Z.

(2023), Critical care explorations, 5(11), e0999

DOI: 10.1097/CCE.0000000000000999

A low serum alkaline phosphatase may signal hypophosphatasia in osteoporosis clinic patients

Ng E, Ashkar C, Seeman E, Schneider HG, Nguyen H, Ebeling PR, Sztal-Mazer S

(2023), OSTEOPOROSIS INTERNATIONAL, 34(2), 327-37

DOI: 10.1007/s00198-022-06597-3

Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH)

Young, Guy; Srivastava, Alok; Kavakli, Kaan; Ross, Cecil R.; Sathar, Jameela; You, Chur Woo; Tran, Huyen; Sun, Jing; Wu, Runhui; Poloskey, Stacey; Qiu, Zhiying; Kichou, Salim; Andersson, Shauna; Mei, Baisong; Rangarajan, Savita

(2023), Lancet, 401(10386), 1427-1437

DOI: 10.1016/S0140-6736(23)00284-2

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM)

Verstovsek, Srdan; Gerds, Aaron; Vannucchi, Alessandro Maria; Al-Ali, Haifa Kathrin; Lavie, David; Kuykendall, Andrew T.; Grosicki, Sebastian; Iurlo, Alessandra; Goh, Yeow Tee; Lazaroiu, Mihaela C.; Egyed, Miklos; Fox, Maria Laura; McLornan, Donal; Harris

(2023), Lancet, 401(10373), 269-280

DOI: 10.1016/S0140-6736(22)02036-0

Response adaptive salvage with KTd and ASCT for functional high-risk multiple myeloma—The Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial

Turner, Rose; Quach, Hang; Horvath, Noemi; Kerridge, Ian H.; Lee, E.; Morris, Emma C.; Kalff, Anna; Khong, Tiffany Tee Fern; Reynolds, John; Spencer, Andrew

(2023), British Journal of Haematology, 202(3), 530-538

DOI: 10.1111/bjh.18914

A sequential cohort study evaluating single-agent KappaMab and KappaMab combined with lenalidomide and low-dose dexamethasone in relapsed and/or refractory kappa light chain-restricted multiple myeloma (AMaRC 01-16)

Spencer, Andrew; Kalff, Anna; Shortt, Jake; Quach, Hang; Wallington-Gates, Craig ; Reynolds, John; Walker, Patricia Ann; Harrison, Simon James; Dunn, Rosanne D.; Wellard, Cameron James

(2023), British Journal of Haematology, 202(4), 801-811

DOI: 10.1111/bjh.18955

1 2 3 4